EN DE
Watch AdAlta Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

AdAlta Limited (1AD) fair value: what the stock is really worth

As of Nov 11, 2026: fair value (intrinsic value) of AdAlta Limited stock A$0.00, price A$0.00, upside +24.0%, quality 27 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare AU · ISIN AU0000001AD2

AL AdAlta Limited logo Thin data Nov 10, 2026

AdAlta Limited

1AD · AU
Fairly valued, weak quality

The stock costs 19% less than our calculation considers fair.

Even on cautious assumptions the value is 24% above the price (A$0.0025).
Fair value A$0.0025 · Fairly valued
Quality 27/100
Weak Growth (revenue 5y −29.4 %/yr in AUD)
High debt
Negative free cash flow
Trails peers (1/6)
Narrow moat 12/100
Thin data
Estimate
Watch AdAlta Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$0.0832 A$0.0020 Fair Value A$0.0025 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range A$0.0020 – A$0.0832 · fair‑value band A$0.0025 – A$0.0025 · the A$0.0020 price screens below the A$0.0025 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow AdAlta in your weekly email

Every Wednesday you see whether AdAlta is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

AdAlta Limited, a clinical-stage biotechnology company, develops cellular immunotherapies for the treatment of solid cancers in Australia. The company also commercializes protein therapeutics.

Show moreShow less

In addition, it engages in the development of AD-21, a protein therapeutic for fibrotic diseases, including lung fibrosis and kidney fibrosis in Phase 1 clinical studies; and WD-34, a discovery stage i-body for the treatment and prevention of malaria and related diseases.

The company was incorporated in 2006 and is based in Hawthorn East, Australia.

Stock analysis

AdAlta Limited (1AD) currently trades at A$0.0020, while our estimate is A$0.0025, so the stock looks roughly fairly valued today (gap 19.4%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: A$0.0025 (bear) to A$0.0025 (bull), the price of A$0.0020 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

AdAlta Limited reported revenue of A$677K in FY2025 versus A$4.0M in FY2021, a compound −35.8%/yr. Reported net income was −A$4.7M in FY2026.

Key figures

Market cap A$6.0M (≈ $4.1M) Micro · P/S ratio 15.9 · Return on equity −62,872% · Return on assets (EBIT) −152% (5-year average) · Operating margin −2,251% · Revenue (TTM) A$404K · Revenue growth (YoY) −67.5% · Free cash flow −A$4.4M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 71% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at 24%, 1AD screens cheaper than that median.

Fair Value

Bear A$0.0025 Fair Value A$0.0025 Bull A$0.0025
Price A$0.0020 · Upside +24.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 27/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 14
How much profit the company makes from its sales and capital
Quality Growth 0
Are margins and returns getting better?
Cashflow 33
Do the profits arrive as real cash?
Financial strength 30
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 11
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−61.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−37.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−29.4%
Start year 2020 (pandemic). Over 10 years: −2.7% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−235.3% (2020) → −646.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Watch 1AD, get fair value alerts →

Compare AdAlta Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 27 · Bottom 25%
Fair Value upside +24.0% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) −67.5% · Bottom 25%
Balance sheet
Debt / equity 3.57× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 16.08× · Priciest 25%
P/S (12 months) 14.72× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)65 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 1AD
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 1AD
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 1AD
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 1AD
argenx SE ARGX $971.55 $908.40 −7% vs 1AD
CSL Limited CSL A$201.68 A$181.40 −10% vs 1AD
Moderna, Inc MRNA $250.83 $158.70 −37% vs 1AD
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 1AD
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 1AD
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 1AD

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

AdAlta Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "AdAlta Limited Fair Value". https://www.fairvalue-calculator.com/stock/1AD

Frequently asked questions

Is AdAlta Limited (1AD) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is A$0.0025 versus a price of A$0.0020, about +24% upside (fairly valued).
What is the fair value of 1AD?
Our estimate for AdAlta Limited is A$0.0025 (as of Nov 10, 2026), built from audited fundamentals. The current price: A$0.0020.
What is the quality score of 1AD?
AdAlta Limited has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for AdAlta Limited (1AD)?
Our calculated price target is the estimate of A$0.0025 (as of Nov 10, 2026). Cautious scenario A$0.0025, optimistic scenario A$0.0025. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the AdAlta Limited stock forecast for 2026?
Our estimate puts fair value at A$0.0025, about +24% upside versus a price of A$0.0020 (fairly valued). Cautious scenario A$0.0025, optimistic scenario A$0.0025. The calculation is refreshed regularly with new filings.
What is the revenue of AdAlta Limited (1AD)?
AdAlta Limited reported trailing-twelve-month revenue of about A$404K (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of AdAlta Limited (1AD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For AdAlta Limited it is A$0.0025 per share (as of Nov 10, 2026), against a price of A$0.0020.
Is AdAlta Limited stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 1AD trades below its calculated fair value: price A$0.0020, fair value A$0.0025, a gap of about +24% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1AD?
No. The price is what the market pays today (A$0.0020); the fair value is what the company's own numbers justify (A$0.0025). For AdAlta Limited the two are A$0.0005 per share apart. That gap is exactly why we show both numbers side by side.
How much is AdAlta Limited worth?
The market values AdAlta Limited at about A$6.0M (market capitalisation, as of Nov 10, 2026). Per share that is A$0.0020; our models calculate a fair value of A$0.0025 per share.
What do the bullish and bearish scenarios say about 1AD?
Our models span a range for AdAlta Limited: cautious scenario A$0.0025, base A$0.0025, optimistic A$0.0025 per share (as of Nov 10, 2026, price A$0.0020). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of AdAlta Limited (1AD)?
Balance-sheet figures for AdAlta Limited (as of Nov 10, 2026): debt of 3.57 per unit of equity. They feed the Quality Score of 27/100, which measures business quality independently of the share price.
How far is 1AD from its 52-week high?
AdAlta Limited trades at A$0.0020, about 71% below its 52-week high of A$0.0070 and at the low of A$0.0020 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0025 is for.
Which stocks are comparable to AdAlta Limited?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is AdAlta Limited stock attractive at the current price?
The data as of Nov 10, 2026: price A$0.0020, calculated fair value A$0.0025 (+24%), Quality Score 27/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. AdAlta Limited currently trades 19% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of AdAlta Limited (1AD)?
The closing price on Nov 11, 2026 was A$0.0020. Our estimate is A$0.0025, about +24% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with AdAlta Limited right now?
The price is below even our cautious bear case (A$0.0025). The market is more pessimistic than our downside scenario. The models converge in a tight band (A$0.0025 to A$0.0025), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of AdAlta Limited

How large is the market capitalisation of AdAlta Limited (1AD)?
The market capitalisation of AdAlta Limited is A$6.0M (≈ $4.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of AdAlta Limited (1AD)?
The price-to-sales ratio of AdAlta Limited is 15.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the return on equity of AdAlta Limited (1AD)?
The return on equity (ROE) of AdAlta Limited is −62,872% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of AdAlta Limited (1AD)?
On an EBIT basis the return on assets of AdAlta Limited is −152% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of AdAlta Limited (1AD)?
The operating margin of AdAlta Limited is −2,251% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at AdAlta Limited (1AD)?
Revenue at AdAlta Limited is growing −67.5% versus a year earlier (3y avg −37.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does AdAlta Limited (1AD) generate?
The free cash flow of AdAlta Limited is −A$4.4M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does AdAlta Limited (1AD) hold?
AdAlta Limited holds more cash than debt, A$1.3M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch AdAlta Limited in the live analysis

One click puts AdAlta Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.